| Literature DB >> 29751552 |
Mihaela Ileana Ionescu1,2, Ovidiu Oniga3.
Abstract
Multi-drug resistant microorganism infections with emerging problems that require not only a prevention strategy, but also the development of new inhibitory compounds. Six previously synthesized 5-arylidene-2-thioxothiazolidin-4-one derivatives 1a⁻f, were screened for inhibitory activity on adenylate kinases of different origins by molecular docking. The compounds 1c and 1d were the most efficient inhibitors of bacterial and some archean adenylate kinases. Hydrogen bond interactions were observed with the residues belonging to the ATP binding site. Moreover human adenylate kinases are poor targets, suggesting that this selectivity offers promising prospectives for refining the structure of our compounds.Entities:
Keywords: adenylate kinase; inhibitory activity; molecular docking; thiazolidine
Mesh:
Substances:
Year: 2018 PMID: 29751552 PMCID: PMC6102543 DOI: 10.3390/molecules23051076
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
The binding energies (kcal/mol) and inhibition constants (µM) of the unliganded AKs or of the enzyme in complex with the substrates or substrate analogs.
| Strain | AK Conformation | ∆G 2 (kcal/mol) | Ki 4 (µM) | ||
|---|---|---|---|---|---|
| ∆G (kcal/mol) | Ki (µM) | ||||
|
| O 5a (4AKE) | −5.26 (±1.7) | 51.32 (±27.53) | 0.020285 | 0.002378 |
| C 5b (1HPQ) | −7.19 (±0.24) | 5.75 (±2.59) | |||
|
| O (4NTZ) | −5.59 (±2.48) | 18.12 (±14.01) | 0.2097 | 0.177056 |
| C (4NU0) | −6.97 (±0.42) | 9.23 (±4.55) | |||
|
| O (2RH5) | −5.81 (±0.32) | 59.53 (±22.31) | 0.000898 | 0.000854 |
| C (2RGX) | −6.77 (±0.4) | 13.21 (±9.37) | |||
|
| O (1NKS/chain A) | −5.87 (±0.09) | 50.61 (±7.75) | 0.000975 | 0.000341 |
| O/C (1NKS/Chain C) | −5.91 (±.44) | 56.04 (±32.03) | |||
| C (1NKS/Chains F) | −6.46 (±0.31) | 34.77 (±14.19) | |||
|
| O (1KHT/Chain A) | −5.69 (±0.35) | 81.06 (±65.92) | 0.000054 | 0.024538 |
| C (1KHT/Chain B) | −6.88 (±0.26) | 9.73 (±4.31) | |||
| Human–AK4 | O (2AR7) | −6.11 (±0.22) | 34.48 (±13.15) | 0.056913 | 0.034455 |
| C (BBW) | −6.52 (±0.27) | 17.85 (±6.62) | |||
| Human–AK5 | O (2BWJ/Chain A) | −6.41 (±0.27) | 22.19 (±13.11) | 0.010154 | 0.020725 |
| C (2BWJ/Chain B) | −5.77 (±0.41) | 70.03 (±40.66) | |||
1 Protein Data Bank Accession number; 2 Binding Energy; 3 Standard Deviation; 4 Inhibition Constant; 5a O = Open conformation of AK, 5b C = Closed-conformation of AK; 6 p-value for 1NKS/chain A and 1NKS/Chains F comparison.
Statistical analysis of the inhibitory activity of the derivatives 1a–f against closed-conformation of bacterial AKs (2RGX, 3HPQ, 4NU0, 1P3J, 1ZIP, 1S3G) and eukaryotic AKs (1Z83, 2C95, 2C9Y, 2BBW, 2BWJ/chain B).
| Derivative | 1 ∆G/Ki | 2 ∆µ | 3 CI 95% | ||
|---|---|---|---|---|---|
|
| ∆G | 0.09867 | 0.923565 | 0.0357 | −0.7821 ≤ ∆µ ≥ 0.8534 |
| Ki | 1.06499 | 0.314617 | 18.4687 | −20.7608 ≤ ∆µ ≥ 57.6981 | |
|
| ∆G | 3.84529 | 0.003935 | 0.933 | 0.3841 ≤ ∆µ ≥ 1.4819 |
| Ki | 2.4127 | 0.039076 | 46.6247 | 2.9091 ≤ ∆µ ≥ 90.3402 | |
|
| ∆G | 4.49226 | 0.001506 | 0.958 | 0.4756 ≤ ∆µ ≥ 1.4404 |
| Ki | 2.2898 | 0.04779 | 33.761 | 0.4075 ≤ ∆µ ≥ 67.1145 | |
|
| ∆G | 1.8825 | 0.09634 | 0.66 | −0.1485 ≤ ∆µ ≥ 1.4685 |
| Ki | 1.87666 | 0.097405 | 21.2967 | −4.8723 ≤ ∆µ ≥ 47.4 | |
|
| ∆G | 2.31486 | 0.04587 | 0.8183 | 0.0186 ≤ ∆µ ≥ 1.6180 |
| Ki | 1.53788 | 0.158459 | 58.1810 | −27.4010 ≤ ∆µ ≥ 143.7630 | |
|
| ∆G | 1.08505 | 0.309513 | 0.325 | −0.3657 ≤ ∆µ ≥1.0157 |
| Ki | 1.21529 | 0.258901 | 27.4042 | −24.5951 ≤ ∆µ ≥ 79.4034 |
1 ∆G (kcal/mol), Ki (µM); 2 the difference between eukaryotic mean and bacterial mean; 3 95% confidence interval of the difference between the eukaryotic mean and bacterial mean.
Analysis of the inhibitory activity of the derivatives 1c and 1d against open and closed-conformations of E. coli and S. pneumoniae AKs.
| Strain | PDB ID | 1c | 1d | ||
|---|---|---|---|---|---|
| ∆G 1 | Ki 2 | ∆G | Ki | ||
|
| 4AKE | −5.82 | 54.17 | −6.65 | 13.26 |
| 3HPQ | −7.24 | 4.97 | −7.27 | 4.68 | |
|
| 4NTZ | −1.91 | 37.12 | −7.33 | 4.22 |
| 4NT0 | −7.13 | 5.92 | −7.74 | 2.13 | |
1 ∆G (kcal/mol); 2 Ki (µM).
Figure 1The interactions of the 1c and 1d derivatives with E. coli and S. pneumoniae AKs.
Figure 2Multiple sequence alignment of the AKs’ sequences. Marked in blue are the residues belonging to the Walker A motif—phosphate-binding loop or P-loop; in the black background was selected the consensus sequence [LIVMFYWCA]-LIVMFYW] (2) -D-G-[FYI]-P-R-X (3) -[NQ] and in yellow were selected the residues strictly conserved in the adenylate kinase family; with pink were selected the Lys and Val residues—well conserved in AKs. Multiple sequence alignment was performed by the Clustal Omega program (https://www.ebi.ac.uk/Tools/msa/clustalo). * (asterisk) indicates positions which have a single, fully conserved amino acid residue; : (colon) indicates conservation between groups of strongly similar properties as following—roughly equivalent to scoring >0.5 in the Gonnet PAM 250 matrix: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW; . (period) indicates conservation between groups of weakly similar properties as following—roughly equivalent to scoring =<0.5 and >0 in the Gonnet PAM 250 matrix: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, FVLIM, HFY
Figure 3The structure of the 5-arylidene-2-thioxothiazolidin-4-one derivatives 1a–f, R = various substituents.